Buprenorphine

Major

Buprenorphine Dimenhydrinate Airmit Explained An increased risk of paralytic ileus Details Buprenorphine Diphenhydramine Banophen Explained An increased risk of respiratory and CNS depression and an increased risk of paralytic ileus Details Buprenorphine Diphenoxylate Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Dipyrone Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Disopyramide Norpace An increased risk of QT interval prolongation Details Buprenorphine Dofetilide Tikosyn An increased risk of QT interval prolongation Details Buprenorphine Dolasetron Anzemet An increased risk of QT interval prolongation and an increased risk of serotonin syndrome Details Buprenorphine Domperidone Explained An increased risk of QT interval prolongation Details Buprenorphine Donepezil Adlarity Explained Reduced seizure threshold and increased risk of QT prolongation Details Buprenorphine Dordaviprone Explained An increased risk of QT interval prolongation Details Buprenorphine Doxepin Prudoxin Explained An increased risk of QT interval prolongation, an increased risk of serotonin syndrome, an increased risk of paralytic ileus and a... Details Buprenorphine Doxylamine Aldex AN Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Droperidol Explained An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details Buprenorphine Duloxetine Explained An increased risk of serotonin syndrome Details Buprenorphine Duvelisib Copiktra Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Ebastine Explained An increased risk of QT interval prolongation Details Buprenorphine Efavirenz Explained Reduced buprenorphine exposure, reduced efficacy of buprenorphine and an increased risk of QT interval prolongation Details Buprenorphine Elagolix Orilissa Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Eletriptan Relpax Explained An increased risk of serotonin syndrome Details Buprenorphine Encorafenib Braftovi Increased risk of QT interval prolongation Details Buprenorphine Enflurane Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Entrectinib Rozlytrek An increased risk of QT interval prolongation Details Buprenorphine Enzalutamide Xtandi Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Eplerenone Inspra Explained Reduced efficacy of diuretics Details Buprenorphine Eribulin Halaven Explained An increased risk of QT interval prolongation Details Buprenorphine Erythromycin Erythrocin Stearate Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Buprenorphine Escitalopram Lexapro Explained An increased risk of QT interval prolongation and an increased risk of serotonin syndrome Details Buprenorphine Esketamine Spravato Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Eslicarbazepine Acetate Aptiom Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Estazolam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Eszopiclone Lunesta Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Ethacrynic Acid Edecrin Explained Reduced efficacy of diuretics Details Buprenorphine Ethchlorvynol Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Ethopropazine Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Ethylmorphine Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Etozolin Explained Reduced efficacy of diuretics Details Buprenorphine Etrasimod Velsipity Explained Increased risk of transient reduction in heart rate, AV conduction, QT interval prolongation and an increased risk of torsade de p... Details Buprenorphine Etravirine Intelence Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Famotidine Calmicid An increased risk of QT interval prolongation Details Buprenorphine Felbamate Felbatol An increased risk of QT interval prolongation Details